Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma
| Autor: | Lori E. Kronish, P. Sullivan, O. F. Ballester, Steven C. Goldstein, Zorsky Pe, Karen K. Fields, Lynn C. Moscinski, A. S. D. Spiers, H. I. Saba, John W. Hiemenz, G. J. Elfenbein |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty Neutropenia Anthracycline Cyclophosphamide medicine.medical_treatment Gastroenterology Dexamethasone Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Idarubicin Humans Etoposide Aged Chemotherapy business.industry Induction chemotherapy Hematology Middle Aged medicine.disease Surgery Survival Rate Regimen Treatment Outcome Female business Multiple Myeloma medicine.drug |
| Zdroj: | British journal of haematology. 96(4) |
| ISSN: | 0007-1048 |
| Popis: | We evaluated toxicities and responses to a novel, dose intensive and time sequenced, chemotherapy programme (DC-IE) in 45 patients with high-risk myeloma. DC-IE consisted of: dexamethasone (days 1-4); cyclophosphamide (day 5); idarubicin and etoposide (days 8-10). Complete response (CR) was achieved in four patients, six patients achieved near complete responses (nCR) and 21 patients achieved a partial remission (PR). Overall response rate was 76% (CI 56-94%) for newly diagnosed patients (n = 21) and 62% (CI 36-81%) for relapsed/refractory patients (n = 24). Toxicities were limited to myelosuppression; two patients died of sepsis during neutropenia (4%). DC-IE is active and tolerable for high-risk multiple myeloma, including patients with relapsed or refractory disease to anthracycline containing regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text